PubRank

Jules L Dienstag

Author PubWeight™ 102.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 9.33
2 Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2008 6.15
3 Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2009 4.90
4 Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 4.33
5 Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 4.27
6 Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009 3.50
7 Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 3.46
8 Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010 3.35
9 Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med 2012 3.28
10 Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010 2.96
11 Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005 2.63
12 Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2010 2.47
13 Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008 2.44
14 American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006 2.14
15 A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011 2.08
16 Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006 2.06
17 Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med 2012 2.06
18 Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008 2.02
19 Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005 1.93
20 Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010 1.78
21 Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2006 1.76
22 Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003 1.62
23 Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002 1.60
24 Hepatitis A--the price of progress. N Engl J Med 2005 1.52
25 Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002 1.40
26 Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2006 1.38
27 Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2009 1.35
28 Commentary: Assessment is an educational tool. Acad Med 2009 1.28
29 Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2011 1.20
30 Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004 1.18
31 HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006 1.13
32 Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010 1.12
33 Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009 1.08
34 Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology 2011 1.07
35 Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009 1.03
36 Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008 0.98
37 Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011 0.98
38 Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2008 0.96
39 The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci 2010 0.93
40 Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One 2012 0.93
41 Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008 0.91
42 Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection. Am J Gastroenterol 2002 0.88
43 Recommendations for prevention, screening, and diagnosis of HBV and HCV infections. J Fam Pract 2010 0.87
44 Perspective: Medical school admissions and noncognitive testing: some open questions. Acad Med 2009 0.86
45 Hepatitis C: a bitter harvest. Ann Intern Med 2006 0.86
46 Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007 0.84
47 Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol 2009 0.79
48 YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int 2011 0.79
49 Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol 2012 0.78
50 The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol 2005 0.78
51 Advancing patient care: integrating new data. Am J Gastroenterol 2006 0.76
52 Hepatitis A: the vaccine dividend. J Infect Dis 2008 0.75
53 In reply to Alexander et al. Acad Med 2013 0.75
54 The case for the new MCAT. N Engl J Med 2012 0.75
55 Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye. Am J Gastroenterol 2010 0.75
56 Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials 2014 0.75
57 Harvard Medical School. Acad Med 2010 0.75